Arbutus Biopharma
ABUS
ABUS
62 hedge funds and large institutions have $44M invested in Arbutus Biopharma in 2019 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 16 increasing their positions, 17 reducing their positions, and 25 closing their positions.
New
Increased
Maintained
Reduced
Closed
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less ownership
Funds ownership: →
less funds holding
Funds holding: →
less first-time investments, than exits
New positions opened: | Existing positions closed:
49% less call options, than puts
Call options by funds: $25K | Put options by funds: $49K
49% less capital invested
Capital invested by funds: $86.5M → $44M (-$42.5M)
Holders
62
Holding in Top 10
–
Calls
$25K
Puts
$49K
Top Buyers
| 1 | +$1.34M | |
| 2 | +$1.31M | |
| 3 | +$1.08M | |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$1.04M |
| 5 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$489K |
Top Sellers
| 1 | -$7.78M | |
| 2 | -$3.44M | |
| 3 | -$1.1M | |
| 4 |
JPMorgan Chase & Co
New York
|
-$1.07M |
| 5 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$884K |